Bluebird talks in Germany may be bad omen for gene therapy in Europe – STAT

When Bluebird Bio secured European approval for its gene therapy to treat beta thalassemia in 2019, the biotech entered pricing negotiations confident that a shared risk plan could convince governments to pay $1.8 million per patient for the one-time, potentially curative treatment.

But two years later, Bluebird is pulling its gene therapy, called Zynteglo, from Germany after government officials would not budge from an offer to pay less than half of the companys list price. The stalemate is a significant setback for Bluebirds business ambitions in Europe, but it also raises broader questions about whether Europe can ever become a viable commercial market for other expensive gene therapies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

Read more:
Bluebird talks in Germany may be bad omen for gene therapy in Europe - STAT